脊髄性筋萎縮症治療薬市場：タイプ、治療法、投与経路別-2025-2030年の世界予測

脊髄性筋萎縮症治療薬市場は、2023年に16億米ドルと評価され、2024年には18億5,000万米ドルに達すると予測され、CAGR 15.40％で成長し、2030年には43億7,000万米ドルに達すると予測されています。

脊髄性筋萎縮症（SMA）治療には、筋変性と筋力低下を特徴とする遺伝性疾患であるSMAの症状を管理・緩和することを目的とした様々な治療法が含まれます。SMA治療の必要性は、その進行性の性質とQOLへの影響に起因しており、症状の緩和と機能改善を提供する治療法が必要とされています。最終用途は、病院、専門クリニック、在宅ケアに及び、遺伝子補充療法、経口薬、支持療法が含まれます。主な成長促進要因としては、認知度と診断率の上昇、遺伝子研究の進歩、バイオ医薬品イノベーションへの投資の増加などが挙げられます。最近のFDA承認は市場拡大にさらに拍車をかけ、新規参入の道を開いています。個別化医療アプローチの開発と最先端治療への幅広いアクセスは大きなビジネスチャンスであり、こうした展望を活用するためには強固な戦略的パートナーシップとセクターを超えた協力が必要です。とはいえ、高い治療費、厳しい規制状況、発展途上地域における限られた患者へのアクセスといった制約が、市場成長の課題となっています。初期段階の診断と遺伝子編集技術の進歩は、技術革新の焦点として推奨されます。企業は、新規の治療的介入を開発するために、疾患の遺伝的背景を理解することに重点を置いた研究への投資から利益を得ることができます。ヘルスケアプロバイダーや保険会社とのパートナーシップを模索し、より良い保険適用や価格設定モデルを交渉することで、経済的な問題に対処できると思われます。SMA治療市場は、医学研究とバイオテクノロジーの飛躍的進歩に大きく影響されるダイナミックな性質を特徴としています。このような微妙な違いを考慮すると、企業は機敏に行動し、競合情勢や患者のニーズを常に見極め、市場の要求に自社のイノベーションを合致させなければならないです。課題はあるもの、戦略的研究イニシアティブと患者中心のソリューションの強化を通じて、市場は成長と変革の可能性を強く秘めています。

市場力学：急速に進化する脊髄性筋萎縮症治療薬市場の主要市場インサイトを公開

脊髄性筋萎縮症治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 脊髄性筋萎縮症の負担増
  • 脊髄性筋萎縮症治療薬に対する有利な払い戻し
  • 政府や非営利団体による啓発プログラムへの取り組み
• 市場抑制要因
  • 治療を成功させるための限られた時間枠
• 市場機会
  • 脊髄性筋萎縮症治療薬の有効性の可能性を広げるための研究開発
  • オンライン薬物流通チャネルの拡大
• 市場の課題
  • 訓練を受けた専門家の不足

ポーターの5つの力：脊髄性筋萎縮症治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：脊髄性筋萎縮症治療薬市場における外部からの影響の把握

外部マクロ環境要因は、脊髄性筋萎縮症治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析脊髄性筋萎縮症治療薬市場における競合情勢の把握

脊髄性筋萎縮症治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス脊髄性筋萎縮症治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、脊髄性筋萎縮症治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨脊髄性筋萎縮症治療薬市場における成功への道筋を描く

脊髄性筋萎縮症治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 脊髄性筋萎縮症の負担増大
    • 脊髄性筋萎縮症治療薬の有利な払い戻し
    • 政府や非営利団体による啓発プログラムの取り組み
  • 抑制要因
    • 治療を成功させるための限られた時間枠
  • 機会
    • 脊髄性筋萎縮症治療薬の効能の可能性を広げる研究開発
    • オンライン医薬品流通チャネルの拡大
  • 課題
    • 訓練を受けた専門家の不足
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 脊髄性筋萎縮症治療薬市場：タイプ別

• タイプ1
• タイプ2
• タイプ3
• タイプ4

第7章 脊髄性筋萎縮症治療薬市場治療別

• 薬物療法
• 遺伝子置換療法

第8章 脊髄性筋萎縮症治療薬市場：投与経路別

• 脊髄内
• オーラル

第9章 南北アメリカの脊髄性筋萎縮症治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の脊髄性筋萎縮症治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの脊髄性筋萎縮症治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Astellas Pharma Inc.
• Biogen Inc.
• Catalyst Pharmaceuticals, Inc.
• Cytokinetics, Incorporated
• F. Hoffmann-La Roche Ltd.
• Ionis Pharmaceuticals, Inc.
• Natera Inc.
• NMD PHARMA A/S
• Novartis AG
• Novo Nordisk A/S
• PerkinElmer, Inc.
• Pfizer Inc.
• PTC Therapeutics, Inc.
• Scholar Rock, Inc.
• Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. SPINAL MUSCULAR ATROPHY TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. SPINAL MUSCULAR ATROPHY TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 28. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 30. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 47. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 48. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 50. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 100. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 102. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 112. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 114. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 117. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Spinal Muscular Atrophy Treatment Market was valued at USD 1.60 billion in 2023, expected to reach USD 1.85 billion in 2024, and is projected to grow at a CAGR of 15.40%, to USD 4.37 billion by 2030.

Spinal Muscular Atrophy (SMA) treatment encompasses a range of therapies that aim to manage and mitigate the symptoms of SMA, a genetic disorder characterized by muscle degeneration and weakness. The necessity for SMA treatments stems from its progressive nature and the impact on quality of life, necessitating therapies that offer symptomatic relief and functional improvement. Applications include gene replacement therapies, oral medications, and supportive care regimes, with end-use spanning hospitals, specialty clinics, and home care settings. Key growth drivers include rising awareness and diagnosis rates, advancements in genetic research, and increased investment in biopharmaceutical innovation. Recent FDA approvals have further spurred market expansion, creating avenues for new entrants. The development of personalized medicine approaches and broader access to cutting-edge treatments represents significant opportunities, necessitating robust strategic partnerships and cross-sector collaboration to leverage these prospects. Nonetheless, limitations like high treatment costs, stringent regulatory landscapes, and limited patient accessibility in developing regions pose challenges to market growth. Advancements in early-stage diagnostics and gene-editing technologies are recommended as focal points for innovation. Companies can benefit from investments in research focused on understanding the disease's genetic underpinnings to develop novel therapeutic interventions. Exploring partnerships with healthcare providers and insurance companies to negotiate better coverage and pricing models could address affordability issues. The SMA treatment market is characterized by its dynamic nature, heavily influenced by breakthroughs in medical research and biotechnology. Given these nuances, companies must stay agile, continuously assessing the competitive landscape and patient needs to align their innovations with market demands. Despite challenges, the market holds strong potential for growth and transformation through strategic research initiatives and enhanced patient-centric solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Spinal Muscular Atrophy Treatment Market

The Spinal Muscular Atrophy Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising burden of spinal muscular atrophy
  • Favorable reimbursements for spinal muscular atrophy treatment
  • Awareness programs initiatives by government and nonprofit organizations
• Market Restraints
  • Limited time-window for successful therapy delivery
• Market Opportunities
  • R&D for expanding possibilities of spinal muscular atrophy treatment efficacy
  • Expansion of online medication distribution channels
• Market Challenges
  • Shortage of trained professionals

Porter's Five Forces: A Strategic Tool for Navigating the Spinal Muscular Atrophy Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Spinal Muscular Atrophy Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Spinal Muscular Atrophy Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Spinal Muscular Atrophy Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Spinal Muscular Atrophy Treatment Market

A detailed market share analysis in the Spinal Muscular Atrophy Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Spinal Muscular Atrophy Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Spinal Muscular Atrophy Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Spinal Muscular Atrophy Treatment Market

A strategic analysis of the Spinal Muscular Atrophy Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Spinal Muscular Atrophy Treatment Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., Biogen Inc., Catalyst Pharmaceuticals, Inc., Cytokinetics, Incorporated, F. Hoffmann-La Roche Ltd., Ionis Pharmaceuticals, Inc., Natera Inc., NMD PHARMA A/S, Novartis AG, Novo Nordisk A/S, PerkinElmer, Inc., Pfizer Inc., PTC Therapeutics, Inc., Scholar Rock, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Spinal Muscular Atrophy Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Type 1, Type 2, Type 3, and Type 4.
• Based on Treatment, market is studied across Drug Therapy and Gene Replacement Therapy.
• Based on Route of Administration, market is studied across Intrathecal and Oral.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising burden of spinal muscular atrophy
    • 5.1.1.2. Favorable reimbursements for spinal muscular atrophy treatment
    • 5.1.1.3. Awareness programs initiatives by government and nonprofit organizations
  • 5.1.2. Restraints
    • 5.1.2.1. Limited time-window for successful therapy delivery
  • 5.1.3. Opportunities
    • 5.1.3.1. R&D for expanding possibilities of spinal muscular atrophy treatment efficacy
    • 5.1.3.2. Expansion of online medication distribution channels
  • 5.1.4. Challenges
    • 5.1.4.1. Shortage of trained professionals
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Spinal Muscular Atrophy Treatment Market, by Type

• 6.1. Introduction
• 6.2. Type 1
• 6.3. Type 2
• 6.4. Type 3
• 6.5. Type 4

7. Spinal Muscular Atrophy Treatment Market, by Treatment

• 7.1. Introduction
• 7.2. Drug Therapy
• 7.3. Gene Replacement Therapy

8. Spinal Muscular Atrophy Treatment Market, by Route of Administration

• 8.1. Introduction
• 8.2. Intrathecal
• 8.3. Oral

9. Americas Spinal Muscular Atrophy Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Spinal Muscular Atrophy Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Spinal Muscular Atrophy Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Astellas Pharma Inc.
• 2. Biogen Inc.
• 3. Catalyst Pharmaceuticals, Inc.
• 4. Cytokinetics, Incorporated
• 5. F. Hoffmann-La Roche Ltd.
• 6. Ionis Pharmaceuticals, Inc.
• 7. Natera Inc.
• 8. NMD PHARMA A/S
• 9. Novartis AG
• 10. Novo Nordisk A/S
• 11. PerkinElmer, Inc.
• 12. Pfizer Inc.
• 13. PTC Therapeutics, Inc.
• 14. Scholar Rock, Inc.
• 15. Takeda Pharmaceutical Company Limited